DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil

Information source: Emory University
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Squamous Cell Carcinoma; Oral Cancer

Intervention: Taxotere (Drug); Cisplatin (Drug); 5-fluorouracil (Drug)

Phase: Phase 2

Status: Terminated

Sponsored by: Emory University

Official(s) and/or principal investigator(s):
Nabil Saba, MD, Principal Investigator, Affiliation: Emory University Winship Cancer Institute

Summary

This is a Phase II study designed to test the efficacy of chemotherapy with docetaxel, cisplatinum (cisplatin) and 5-fluorouracil in patients with squamous cell carcinoma of the oral cavity to determine what effects these agents may have on cancer cells.

Clinical Details

Official title: Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints

Study design: Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Number of Patients Who Had Response by RECIST Criteria (Response Evaluation Criteria in Solid Tumors)

Secondary outcome: Measure the Acetylated Tubulin Expression and Correlate With Clinical Outcome.

Detailed description: This is a Phase II study designed to test the efficacy of chemotherapy with docetaxel, cisplatinum, and 5-fluorouracil in patients with squamous cell carcinoma of the oral cavity to determine what effects these agents may have on cancer cells. Approximately 60 patients will take part at multi-sites with potentially 20 patients participating at the Emory Winship Cancer Institute in Atlanta, Georgia.

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Histologically or cytologically proven squamous cell carcinoma of the oral cavity.

- Primary tumor sites eligible: oral cavity. Although they are admittedly of squamous

cell types, the following tumors will be excluded because their responsiveness to chemotherapy may differ: tumors of the nasal and paranasal cavities and of the nasopharynx. Oral cavity tumors with mandible invasion are excluded because the tumor biology and management of these tumors is more complex and will likely include upfront surgical resection.

- Stage 3 or 4 disease without evidence of distant metastases verified by chest x-ray,

abdominal ultrasound, or CT scan (liver function test abnormalities); bone scan in case of local symptoms.

- At least one uni- or bi-dimensionally measurable lesion.

- Age ≥ 18 years.

- WHO (World Health Organization)performance status of 2 or less.

- No active alcohol addiction.

- Final eligibility for a clinical trial is determined by the health professionals

conducting the trial. Exclusion Criteria:

- Pregnant or breast feeding

- Previous malignancies at other sites, with the exception of adequately treated in

situ carcinoma of the cervix uteri, basal, or squamous cell carcinoma of the skin or other cancer curatively treated by surgery and with no evidence of disease for at least 5 years.

- Any prior treatment with radiotherapy or chemotherapy is an exclusion criterion.

- Patients who experience an involuntary weight loss of more than 25% of their body

weight in the 2 months preceding study entry.

- Concurrent treatment with any other anti-cancer therapy.

- Participation in an investigational trial within 30 days of study entry.

- Patients with a history of severe hypersensitivity reaction to Taxotere® or other

drugs formulated with polysorbate 80.

- No previous chemotherapy or radiotherapy for any reason and no previous surgery for

SCCHN [squamous cell carcinoma of the head and neck] (other than biopsy) are allowed at the time of study entry.

- Final eligibility for a clinical trial is determined by the health professionals

conducting the trial.

Locations and Contacts

Emory University Winship Cancer Institute, Atlanta, Georgia 30322, United States
Additional Information

Starting date: August 2006
Last updated: March 30, 2011

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017